Loading...
Market
Monte Rosa market cap levels following Novartis deal by end of 2025?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Market capitalization data from financial markets
Story
Monte Rosa and Novartis Sign $150M Global License Agreement with $2.2B Milestone for Molecular Glue Degraders
Oct 28, 2024, 12:56 PM
Monte Rosa Therapeutics has announced a global license agreement with Novartis to advance T and B cell-modulating VAV1-directed molecular glue degraders. The deal includes a $150 million upfront payment from Novartis, with potential future milestone payments reaching up to $2.2 billion. The agreement aims to develop, manufacture, and commercialize innovative drug candidates, including MRT-6160, which is currently in Phase 1 trials. This partnership is expected to significantly impact the field of immunology and inflammation (I&I) therapeutics. Monte Rosa's CEO Markus Warmuth, Chief Medical Officer Filip Janku, and Chief Data & Information Officer Jocelyn Castle are key figures in this collaboration. Monte Rosa's stock jumped 32.1% pre-market following the announcement, and the deal includes a 30% US P&L share for Monte Rosa.
View original story
Similar markets
Top 3 • 25%
Top 5 • 25%
Top 10 • 25%
Outside Top 10 • 25%
Up to $150 million • 25%
$150 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
New partnership with a major pharma • 25%
Expansion of existing partnerships • 25%
No new partnership • 25%
Acquisition by another company • 25%
Positive response • 25%
Neutral response • 25%
Negative response • 25%
Mixed response • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Roche outperforms Merck • 25%
Merck outperforms Roche • 25%
Both perform similarly • 25%
Both underperform the market • 25%
Revenue decrease due to MRT-6160 • 25%
Revenue increase due to MRT-6160 • 25%
No significant financial impact • 25%
MRT-6160 discontinued • 25%
Novartis outperforms competitors • 25%
Novartis performs equally as competitors • 25%
Novartis underperforms competitors • 25%
Stock performance is inconclusive • 25%